

ASX Release

Anatara Appendix 4C

BRISBANE & MELBOURNE, 30th January 2019: Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2018. The Company's cash position at the end of the quarter stood at \$1.5m. The Company also had \$4,500,000 in deposits with terms of greater than 90 days. Expenditure during the quarter was in line with forecast.

On 14th January 2019, the Company received \$1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.

The Company announced on 29th October 2018, it had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product licensed to Zoetis Inc. The animal health product Detach has the approved label, *"To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets"*.

Anatara was also delighted to announce the appointment of Mr Steven Lydeamore as Chief Executive Officer (CEO) on 14th November. Mr Lydeamore has 26 years' international experience in the pharmaceutical industry, working in Australia, USA and Canada. He brings a strong track record of successfully commercialising products on a global scale, thereby driving sales growth and shareholder value.

The Company's Product Development Advisory Board, comprising prominent independent experts in human gastrointestinal health to assist the Company in developing our first human health product, held its inaugural meeting. The Company's product candidate known as the **Gastrointestinal ReProgramming (GaRP)** dietary supplement, an evidence-based product aimed at restoring and maintaining gut health, is well advanced in proof of concept studies.

Looking ahead to 2019, Anatara remains focused on its new business strategy in human health, and in particular the development and partnering of its GaRP dietary supplement. With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

For more information please contact:

General inquiries	Media inquiries
Steven Lydeamore CEO, Anataro Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataro.com	Jane Lowe Managing Director, IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anataro Lifesciences Ltd

Anataro Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataro is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.



Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Anatara Lifesciences Ltd (ASX: ANR)

ABN

41 145 239 872

Quarter ended ("current quarter")

31 December 2018

Consolidated statement of cash flows	Current quarter A'000	Year to date (6 months) A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	670
1.2 Payments for		
(a) research and development	(247)	(434)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(527)	(1,078)
(f) administration and corporate costs	(417)	(1,039)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	20	104
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	17
1.8 Other	56	107
1.9 Net cash from / (used in) operating activities	(1,115)	(1,653)

Consolidated statement of cash flows		Current quarter A'000	Year to date (6 months) A'000
2.	Cash flows from investing activities	-	-
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments (<i>term deposits of greater than 90 days</i>)	(1,000)	(3,000)
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) property, plant and equipment		
	(b) businesses (see item 10)	-	-
	(c) investments (<i>term deposits of greater than 90 days</i>)	-	4,700
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(1,000)	1,700

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	3,610	1,448
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,115)	(1,653)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,000)	1,700
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	1,495	1,495

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	695	110
5.2	Call deposits (<i>deposits with terms of less than or equal to 90 days</i>)	800	3,500
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,495 (*)	3,610

(*) As at 31 December 2018, other than the cash and cash equivalents presented above, the Company also had \$4,500,000 (30 September 2018: \$3,500,000) in deposits with terms of greater than 90 days.

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	180
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Item 6.1 Reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements).

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	
-	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		
-		

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	382
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	474
9.6 Administration and corporate costs	347
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	1,203

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: 
(Chief Executive Officer)

Date: 30 January 2019

Print name: Steven Lydeamore

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.